- Home
- LTC vs PVLA Comparison
LTC vs PVLA Comparison
Compare LTC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTC | PVLA |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | LTC | PVLA |
|---|---|---|
| Price | $36.19 | $112.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $40.00 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 470.8K | 222.8K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.96% | N/A |
| EPS Growth | ★ 23.53 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $262,854,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $104,350.18 |
| P/E Ratio | $76.83 | ★ N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $33.64 | $20.82 |
| 52 Week High | $40.80 | $151.18 |
Technical Indicators
Market Signals| Indicator | LTC | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 48.87 |
| Support Level | $35.52 | $109.68 |
| Resistance Level | $37.00 | $118.23 |
| Average True Range (ATR) | 0.91 | 7.16 |
| MACD | 0.04 | 0.65 |
| Stochastic Oscillator | 45.30 | 59.45 |
Price Performance
Historical ComparisonAbout LTC LTC Properties Inc.
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.